Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1682

Sort by

Sort Order Select

Journal Articles

Integrated omics approaches to predict T-LBL relapse risk

Guillaume P. Andrieu, Vahid Asnafi

Blood (2021) 137 (17): 2280–2282.

https://doi.org/10.1182/blood.2020009599

Published: 2021

Journal Articles

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

Sofie Gottschalk Højfeldt, Kathrine Grell, Jonas Abrahamsson, Bendik Lund, Kim Vettenranta, Ólafur G. Jónsson, Thomas L. Frandsen, Benjamin O. Wolthers, Hanne Vibeke Marquart, Goda Vaitkeviciene, Kristi Lepik, Mats Heyman, Kjeld Schmiegelow, Birgitte Klug Albertsen

Blood (2021) 137 (17): 2373–2382.

https://doi.org/10.1182/blood.2020006583

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

Blood (2020) 136 (10): 1161–1168.

https://doi.org/10.1182/blood.2020005064

Published: 2020

Includes: Supplemental data

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Jason Moran, Kenneth A. Bauer

Blood (2020) 135 (5): 344–350.

https://doi.org/10.1182/blood.2019000917

Published: 2020

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Single Cell Transcriptomics Predicts Relapse in Infants with Acute Lymphoblastic Leukemia

Tito Candelli, PhD, Pauline Schneider, Patricia Garrido Castro, PhD, Luke A Jones, PhD, Rob Pieters, MDPhDMSc, Thanasis Margaritis, PhD, Ronald W. Stam, PhD, Frank C.P. Holstege, PhD

Blood (2019) 134 (Supplement_1): 3951.

https://doi.org/10.1182/blood-2019-123052

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2

Ryan C Henrici, PhD BS, Casey Sautter, MDMS, Robert Opoka, MMED, Ruth Namazzi, MD, Gregory S Park, Dibyadyuti John, PhD, Andrea L Conroy, PhD, Russell E. Ware, MD PhD, Chandy C. John, MDMS

Blood (2019) 134 (Supplement_1): 2283.

https://doi.org/10.1182/blood-2019-129566

Published: 2019

Journal Articles

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Brendan Rasor, PharmD, Tyler Dickerson, PharmD, Qiuhong Zhao, MS, Jonathan E Brammer, MD, Karilyn Larkin, MD, Samantha Jaglowski, MDMPH, Alice S. Mims, MD, Sam Penza, MD, Sumithira Vasu, MDMBBS, Sarah A Wall, MD, Basem M. William, MRCP,MD, Ayman Saad, MD, Julianna Roddy, PharmD, Hannah K. Choe, MD, Marcin Puto, PharmD

Blood (2019) 134 (Supplement_1): 5715.

https://doi.org/10.1182/blood-2019-123657

Published: 2019

Journal Articles

Co-Transplantation of Mesenchymal Stem Cells Further Improves the Prognosis of Allo-HSCT in the Treatment of High Risk and Refractory/Relapse Hematologic Malignancies: A Single-Center Retrospective Study of 175 Patients

Jinhua Ren, Xiaofeng Luo, Minmin Chen, Min Xiao, Qian Li, Kangni Lin, Zhihong Zheng, Zhizhe Chen, Jianda Hu, PhD, Ting Yang

Blood (2019) 134 (Supplement_1): 5721.

https://doi.org/10.1182/blood-2019-127595

Published: 2019

Journal Articles

Outcomes of AML Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation with Adverse Risk Disease By European Leukemianet Classification: A Single Center Retrospective Analysis

Zane Chiad, MD, Clark Alsfeld, MD, Robert Collins, MD MPH, Brion Randolph, MD, Georges Nahhas, Robert K. Stuart, MD, Amarendra K. Neppalli, MD, Irl Brian Greenwell, MD, Kathy Edwards, PharmD, BCPS, BCOP, HRM, Laura Milligan, MSN, FNP, BC, AOCN, Lauren Pearce, FNP-BC, Brian T. Hess, MD

Blood (2019) 134 (Supplement_1): 5723.

https://doi.org/10.1182/blood-2019-128172

Published: 2019

Journal Articles

Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

Herve Ghesquieres, MD PhD, Youenn Drouet, PhD, Sarah Huet, PharmD PhD, Guillaume Cartron, Marie-Helene Delfau, MD PhD, Fritz Offner, MD, Pauline Brice, Luc Xerri, MD PhD, Reda Bouabdallah, Gilles A. Salles, MD PhD

Blood (2019) 134 (Supplement_1): 2780.

https://doi.org/10.1182/blood-2019-130357

Published: 2019

Journal Articles

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Daniel J. DeAngelo, MD PhD, Brian A Jonas, MD PhD, Jane L. Liesveld, MD, Dale L. Bixby, MD, Anjali S. Advani, MD, Paula Marlton, MBBS (Hons), FRACP, FRCPA, Michael E O'Dwyer, MD, William E. Fogler, PhD, John L. Magnani, PhD, Mary M Chen, MD PhD, Eric J. Feldman, MD, Helen M Thackray, MD, Pamela S. Becker, MD PhD

Blood (2019) 134 (Supplement_1): 2690.

https://doi.org/10.1182/blood-2019-123744

Published: 2019

Journal Articles

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Kinjal Shah, MS, Julhash U. Kazi, PhD

Blood (2019) 134 (Supplement_1): 2752.

https://doi.org/10.1182/blood-2019-129823

Published: 2019

Journal Articles

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Erika Borlenghi, MD, Chiara Pagani, MD, Michele Malagola, MD, Diego Bertoli, PhD, Francesca Schieppati, MD, Silvana Archetti, PhD, Angela Passi, MD, Cinzia Lamorgese, Chiara Cattaneo, MD, Nicola Polverelli, Margherita Sciumé, Rosa Daffini, MD, Doriana Gramegna, MD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 2695.

https://doi.org/10.1182/blood-2019-126074

Published: 2019

Journal Articles

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

Blood (2019) 134 (Supplement_1): 2755.

https://doi.org/10.1182/blood-2019-122311

Published: 2019

Journal Articles

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Katherine Tarlock, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Yi-Cheng Wang, Robert B. Gerbing, Laura Pardo, Fangyan Dai, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Jessica A. Pollard, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 2699.

https://doi.org/10.1182/blood-2019-127100

Published: 2019

NARROW

Integrated omics approaches to predict T-LBL relapse risk

Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia

How I treat warm autoimmune hemolytic anemia

Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Single Cell Transcriptomics Predicts Relapse in Infants with Acute Lymphoblastic Leukemia

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Profound Alteration of Host Response in Severe Malarial Anemia By Sickle Cell Disease: Reduction of Parasite Sequestration and Inflammation, Upregulation of Angiopoietin-2

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Co-Transplantation of Mesenchymal Stem Cells Further Improves the Prognosis of Allo-HSCT in the Treatment of High Risk and Refractory/Relapse Hematologic Malignancies: A Single-Center Retrospective Study of 175 Patients

Outcomes of AML Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation with Adverse Risk Disease By European Leukemianet Classification: A Single Center Retrospective Analysis

Implication of Inherited Genetic Variants Associated with Follicular Lymphoma Susceptibility in the Prognosis of Patients Treated By Immunochemotherapy in PRIMA Study

High E-Selectin Ligand Expression Contributes to Chemotherapy-Resistance in Poor Risk Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML) Patients and Can be Overcome with the Addition of Uproleselan

Identification of a New Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia and Studies on Its Mechanism of Action

Post Induction and Post Consolidation Measurable/Minimal Residual Disease Predict Relapse in NPM-1 Positive AML. Outcome of Treatment Relapse. a Single Center Experience

Value of Flow Cytometry for MRD-Based Relapse Prediction in B-Cell Precursor Acute Lymphoblastic Leukemia in a Multi-Center Setting

CD117 Expression Is Associated with Cytogenetic and Molecular Profiles and Outcome in Pediatric Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only